Keywords: harsh, blow, biogen, psoriasis, drug, amevive, stumbles
Harsh blow for Biogen as psoriasis drug Amevive stumbles in Europe
Article | 03 March 2003
Following a negative review from the European Union's Committee forProprietary Medicinal Products, Biogen has withdrawn its application for approval of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
